Concepedia

Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’

Patrick Schöffski, Olivier Mir, Bernd Kasper, Zsuzsanna Pápai, Jean‐Yves Blay, Antoîne Italiano, Charlotte Benson, Kateřina Kopečková, Nasim Ali, Palma Dileo,

European Journal of Cancer · 2020 · 67 citations · 23 references

DOI

Concepts

References

23

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett et al. · The Lancet · 2006 · 2.6K citations

, , +8

Two Hundred Gastrointestinal Stromal Tumors

Ronald P. DeMatteo, Jonathan J. Lewis, Denis H. Y. Leung et al. · Annals of Surgery · 2000 · 2.5K citations · Full text

, , +15

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri, Peter Reichardt, Yoon‐Koo Kang et al. · The Lancet · 2012 · 1.4K citations · Full text

, , +8

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

Ronald P. DeMatteo, Karla V. Ballman, Cristina R. Antonescu et al. · The Lancet · 2009 · 1.4K citations · Full text

, , +11

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

F. Michael Yakes, Jason Chen, Jenny Tan et al. · Molecular Cancer Therapeutics · 2011 · 1.3K citations · Full text

, , +17